Comments

Protagonist Therapeutics

Q: What sector and industry does Protagonist Therapeutics (PTGX) operate in?

Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

PTGXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$36.82

0.280.77%

At close: -

$36.82

0.000.00%

After Hours: Jan 17, 4:00 PM EDT

Protagonist Therapeutics (PTGX) Forecast

News Earnings Protagonist Therapeutics (PTGX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Overview Rating

Good

Technicals Analysis

100

0100

Financials Analysis

0100

Protagonist Therapeutics (NASDAQ:PTGX) Stock Quotes, Forecast and News Summary

Protagonist Therapeutics Stock (NASDAQ: PTGX) stock price, news, charts, stock research, profile.

Open	$36.98
Close	$36.82
Volume / Avg.	485.31K / 669.69K
Day Range	$36.34 - $37.43
52 Wk Range	23.17 - 48.89
Market Cap	$2.19B
P/E Ratio	13.34
Dividend Yield	-
Exchange	NASDAQ
RSI	40
Short Interest	6.46%
Days to Cover	5.5

Recent News

Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday

Avi Kapoor

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.

Vandana Singh

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jul 24

Aug 24

Sep 24

Nov 24

Dec 24

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$36.98
Close	$36.82
Volume / Avg.	485.31K / 669.69K
Day Range	$36.34 - $37.43
52 Wk Range	23.17 - 48.89
Market Cap	$2.19B
P/E Ratio	13.34
Dividend Yield	-
Exchange	NASDAQ
RSI	40
Short Interest	6.46%
Days to Cover	5.5

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Protagonist Therapeutics (PTGX) stock?

You can purchase shares of Protagonist Therapeutics (NASDAQ:PTGX) through any online brokerage.

View our list of the best stock brokerages

Who are Protagonist Therapeutics (PTGX) competitors?

Other companies in Protagonist Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Twist Bioscience (NASDAQ:TWST), MoonLake (NASDAQ:MLTX), Centessa Pharmaceuticals (NASDAQ:CNTA) and SpringWorks Therapeutics (NASDAQ:SWTX).

What is the forecast, or price target, for Protagonist Therapeutics (PTGX) stock?

Protagonist Therapeutics has a consensus price target of $50.64.

What is the current price for Protagonist Therapeutics (PTGX)?

The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $36.82 last updated January 17, 2025 at 4:00 PM EST.

Does Protagonist Therapeutics (PTGX) pay a dividend?

There are no upcoming dividends for Protagonist Therapeutics.

When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?

Protagonist Therapeutics’s Q4 earnings are confirmed for Tuesday, February 25, 2025.

Is Protagonist Therapeutics (PTGX) going to split?

There is no upcoming split for Protagonist Therapeutics.

What sector and industry does Protagonist Therapeutics (PTGX) operate in?

Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.